Table 4b.
Anti-RBD-IgG1 and IgG4 GMTs for all four formulation cohorts at Day0 (pre-vaccination), and Day56 (post second-dose).
| Formulation | Subjects | IgG1 Titer |
IgG4 Titer |
D56-G1/G4 Ratio GMR | ||||
|---|---|---|---|---|---|---|---|---|
| D0 GMT | D56 GMT | GMFR | D0 GMT | D56 GMT | GMFR | |||
| A | 89 | 74 | 2696 | 36·25 | 31 | 57 | 1·84 | 48·7 |
| B | 90 | 74 | 2940 | 39·7 | 31 | 76 | 2·48 | 37·1 |
| C | 89 | 65 | 1884 | 28·92 | 27 | 50 | 1·81 | 38·0 |
| D | 89 | 89 | 2219 | 24·94 | 32 | 57 | 1·79 | 38·4 |
IgG: Immunoglobulin G; RBD: Receptor binding protein; GMT: Geometric mean titer; D0: Day0, D56: Day56.
Note: GMFR for each formulation cohort is calculated from the Geometric Mean for the Fold Rise in titer at Day56 vs Day0 time-point for each cohort; Geometric Mean Ratio was calculated for IgG1 to IgG4 titers at Day56 for all four cohorts.